Citations

Clear

120 citation(s) found for "Abu Dayyeh, Barham K".

493. EFFECTIVENESS OF TRANSORAL INCISIONLESS FUNDOPLICATION (TIF) WITHOUT OR WITH HIATAL HERNIA REPAIR (CTIF) IN PATIENTS WITH GERD AND CHRONIC COUGH
Almario, Jose Antonio , Dunbar, Kerry B., Parker, Brett , Brewer-Gutierrez, Olaya, Janu, Peter , Sohagia, Amit, Khara, Harshit S. , Dayyeh, Barham Abu, Sharaiha, Reem Z. , Zarnegar, Rasa , Ihde, Glenn , Nguyen, Ninh T. , Chang, Kenneth , Swei, Eric C. , Yadlapati, Rena , Murray, Michael J. , Diehl, David L. , Kolb, Jennifer M. , Canto, Marcia Irene

Mayo Clinic

Diseases of the Esophagus | September 2, 2024 | Volume: 37 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doae057.230 Get It

Abstract Background GERD is a common cause of chronic cough. Although barrier therapy with laparoscopic fundoplication is highly effective for typical GERD symptoms, the response rates are variable for chronic cough. We hypothesized that transoral incisionless fundoplication (TIF) or TIF with hiatal hernia repair (cTIF) may be a suitable alternative for medically refractory cough associated with GERD. Aim We prospectively s studied the effectiveness and safety of TIF/cTIF in patients with chronic cough and proven GERD. Methods Patients with GERD and extra-esophageal symptoms from 10 academic and community medical centers (TIF Registry), elevated GERD-HRQL score +/- Reflux Symptom Index (RSI) >13 and pathologic reflux by esophageal pH-metry, or erosive esophagitis/Barrett’s esophagus were evaluated before and after a minimum 6 months post TIF/cTIF performed by gastroenterologists and surgeons. Patients with history of prior foregut/bariatric surgery, chronic obstructive or interstitial lung disease, or prior lung transplant were excluded. The primary outcome was improvement in RSI score at last follow-up compared to baseline. Secondary outcomes were: 1) normalization of RSI (<13), 2) improvement in cough sub-scores of RSI (decrease ≥ 2 points or to 0 on a 5-point scale), 3) GERD symptom improvement (>50% decrease in GERD-HRQL, or < 2 in all sub-scores) 4) discontinuation of proton pump inhibitor (PPI), and 5) overall patient satisfaction. We further analyzed response in patients with cough-predominant phenotype (chief complaint of cough and RSI troublesome cough subscore ≥2). Results 198 patients with cough and GERD successfully underwent TIF/cTIF (Table 1) without serious adverse events. Greater than 6-month follow-up was available for 177 patients at a median of 12 months [IQR 6,12]. Median RSI score decreased from 18 [IQR 13, 27] to 5 [IQR 2, 11] (p < 0.0001), median change 11 [IQR5,11]. 83% of patients with elevated baseline RSI normalized their scores. 75% of patients had improvement of cough when lying down (median: 1 point [IQR 0,3]), and 72% of patients had improvement of troublesome cough (median: 1 point [IQR 1,3]). 83% of patients successfully discontinued or decreased PPI to occasional use. Patient satisfaction improved from a baseline of 5.6% to 68.8% (p <0.0001). Compared to patients without cough-predominant symptoms, cough-predominant patients (n=108) experienced an additional 4.2-point decrease in in RSI score (p = 0.01) and 1.5-point decrease in troublesome cough sub-scores (p<0.0001). Patients with regurgitation phenotype were more likely to have a favorable cough response at 6 months (p<0.0001). In appropriately selected patients, cTIF and TIF were comparable for cough, GERD-HRQL, RSI, and PPI responses. Conclusion TIF/cTIF are effective and safe alternative barrier therapies for patients with pH-positive cough-predominant GERD.
Utilization of an artificial intelligence–enhanced, web‐based application to review bile duct brushing cytologic specimens: A pilot study
Marya, Neil B. , Powers, Patrick, Bois, Melanie C. , Hartley, Christopher , Kerr, Sarah E. , Thangaiah, Judith Jebastin, Cantley, Richard , Gleeson, Ferga C. , Law, Ryan , Martin, John A. , Petersen, Bret T. , Levy, Michael J. , Jebastin, Judith A S , Cantley, Richard , Law, Ryan J, Maleki, Zahra , Pantanowitz, Liron , Petersen, Bret, Marya, Neil B. , Hartley, Christopher P , Norton, Daniel, Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Gores, Gregory J. , Maleki, Zahra , Petersen, Bret T. , Storm, Andrew C. , Graham, Rondell P.

Mayo Clinic

Cancer Cytopathology | August 29, 2024 | Volume: 132 | Issue: 12 | Pages: 779-787

10.1002/cncy.22898 | PMID 39207803 Get It

Abstract Background The authors previously developed an artificial intelligence (AI) to assist cytologists in the evaluation of digital whole‐slide images (WSIs) generated from bile duct brushing specimens. The aim of this trial was to assess the efficiency and accuracy of cytologists using a novel application with this AI tool. Methods Consecutive bile duct brushing WSIs from indeterminate strictures were obtained. A multidisciplinary panel reviewed all relevant information and provided a central interpretation for each WSI as being “positive,” “negative,” or “indeterminate.” The WSIs were then uploaded to the AI application. The AI scored each WSI as positive or negative for malignancy (i.e., computer‐aided diagnosis [CADx]). For each WSI, the AI prioritized cytologic tiles by the likelihood that malignant material was present in the tile. Via the AI, blinded cytologists reviewed all WSIs and provided interpretations (i.e., computer‐aided detection [CADe]). The diagnostic accuracies of the WSI evaluation via CADx, CADe, and the original clinical cytologic interpretation (official cytologic interpretation [OCI]) were compared. Results Of the 84 WSIs, 15 were positive, 42 were negative, and 27 were indeterminate after central review. The WSIs generated on average 141,950 tiles each. Cytologists using the AI evaluated 10.5 tiles per WSI before making an interpretation. Additionally, cytologists required an average of 84.1 s of total WSI evaluation. WSI interpretation accuracies for CADx (0.754; 95% CI, 0.622–0.859), CADe (0.807; 95% CI, 0.750–0.856), and OCI (0.807; 95% CI, 0.671–0.900) were similar. Conclusions This trial demonstrates that an AI application allows cytologists to perform a triaged review of WSIs while maintaining accuracy.
Using Pre-operative Insulin Dose to Predict Diabetes Remission After Roux-En-Y Gastric Bypass and Sleeve Gastrectomy
Salameh, Yara , Ghanem, Omar M. , Abi Mosleh, Kamal , Ghanem, Omar M , Ghusn, Wissam , Salameh, Yara , Mosleh, Kamal Abi , Shah, Mithun V , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Surgical Innovation | August 6, 2024 | Volume: 31 | Issue: 5 | Pages: 484-492

10.1177/15533506241273368 | PMID 39105388 Get It

Background Obesity is intricately associated with type-2 diabetes (T2D) and other cardiovascular conditions, increasing morbidity, mortality, and health care costs. Metabolic and bariatric surgeries (MBS) have shown promising results in significant weight loss and T2D remission, but existing predictive scores for post-MBS diabetes remission do not consider insulin dosage, potentially overlooking a critical factor. Methods A retrospective analysis of patients with T2D who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). The study focused on insulin dosage impact, divided into quartiles, on remission rates post-MBS. The effectiveness of RYGB vs SG was compared within insulin dose quartiles with up to 5 years of follow up. Results A total of 508 patients (64% female, 94.9% White, mean age 53.5 ± 10.5 years, BMI (46.0 ± 8.3 kg/m 2 ) were included in the analysis. This study demonstrates a profound association between insulin dosage quartiles and T2D remission after MBS. Patients with lower insulin requirements showed superior remission rates; those in the lowest quartile had remission rates of 73%, 70%, and 62% at 1, 3, and 5 years, respectively, compared to 34%, 37%, and 36% in the highest quartile ( P < 0.001 across all intervals). RYGB surgery showed a significantly better remission in the second and third insulin quartiles, suggesting its effectiveness over SG for patients with mid-range insulin requirements. Conclusion This study underscores the importance of considering insulin dosage when predicting T2D remission post-MBS. The findings advocate for a more nuanced selection of MBS procedures based on individual insulin profiles, potentially enhancing diabetes remission outcomes.
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures
Cooley, Matthew A. , Schneider, Amber, Fritcher, Emily G. Barr , Milosevic, Dragana , Levy, Michael J. , Bridgeman, Amber R. , Martin, John A. , Petersen, Bret T. , Dayyeh, Barham K. Abu , Law, Ryan , Garimella, Vishal, Jenkins, Sarah M. , Yin, Jun, Roberts, Lewis R. , Kipp, Benjamin R. , Ferrándiz‐Pulido, Carla , Schneider, Amber R, Abu Dayyeh, Barham K , Storm, Andrew C , Law, Ryan J, Vargas, Eric J , Roberts, Lewis R , Kipp, Benjamin , Chandrasekhara, Vinay , Barr Fritcher, Emily G , Bridgeman, Amber R , Levy, Michael J. , Storm, Andrew C. , Vargas, Eric J. , Zemla, Tyler , Gores, Gregory J. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology | June 21, 2024 | Volume: 81 | Issue: 2 | Pages: 453-464

10.1097/hep.0000000000000970 | PMID 38905442 Get It

Background and Aims: Early identification of malignant biliary strictures (MBSs) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography. We aimed to evaluate the use of methylated DNA markers (MDMs) from biliary brushings to enhance MBS detection in a prospective cohort. Approach: Candidate MDMs were evaluated for their utility in MBS diagnosis through a series of discovery and validation phases. DNA was extracted from biliary brushing samples, quantified, bisulfite-converted, and then subjected to methylation-specific droplet digital polymerase chain reaction. Patients were considered to have no malignancy if the sampling was negative and there was no evidence of malignancy after 1 year or definitive negative surgical histopathology. Results: Fourteen candidate MDMs were evaluated in the discovery phase, with top-performing and new markers evaluated in the technical validation phase. The top 4 MDMs were TWIST1, HOXA1, VSTM2B, and CLEC11A, which individually achieved AUC values of 0.82, 0.81, 0.83, and 0.78, respectively, with sensitivities of 59.4%, 53.1%, 62.5%, and 50.0%, respectively, at high specificities for malignancy of 95.2%–95.3% for the final biologic validation phase. When combined as a panel, the AUC was 0.86, achieving 73.4% sensitivity and 92.9% specificity, which outperformed cytology and fluorescence in situ hybridization (FISH). Conclusions: The selected MDMs demonstrated improved performance characteristics for the detection of MBS compared to cytology and FISH. Therefore, MDMs should be considered viable candidates for inclusion in diagnostic testing algorithms.
Unraveling the Variability of Human Satiation: Implications for Precision Obesity Management
Cifuentes, Lizeth , Añazco, Diego , Fansa, Sima , McRae, Alison , Madhusudhan, Sunil, Kolkin, Elle, Ryks, Michael, Harmsen, William S. , Dayyeh, Barham Abu, Hensrud, Donald D. , Camilleri, Michael , Acosta, Andrés , Acosta, Andres , Anazco, Diego , McRae, Alison , Abu Dayyeh, Barham, Hensrud, Donald, Camilleri, M , O'Connor, Timothy R , Hurtado, Maria D. , Ghusn, Wissam , Campos, Alejandro , Ciotlos, Serban, Dayyeh, Barham K. Abu

Mayo Clinic

No container title available | May 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4402499/v1 | PMID 38826309 Get It

Abstract Satiation is the physiologic process that regulates meal size and termination, and it is quantified by the calories consumed to reach satiation. Given its role in energy intake, changes in satiation contribute to obesity's pathogenesis. Our study employed a protocolized approach to study the components of food intake regulation including a standardized breakfast, a gastric emptying study, appetite sensation testing, and a satiation measurement by an ad libitummeal test. These studies revealed that satiation is highly variable among individuals, and while baseline characteristics, anthropometrics, body composition and hormones, contribute to this variability, these factors do not fully account for it. To address this gap, we explored the role of a germline polygenic risk score, which demonstrated a robust association with satiation. Furthermore, we developed a machine-learning-assisted gene risk score to predict satiation and leveraged this prediction to anticipate responses to anti-obesity medications. Our findings underscore the significance of satiation, its inherent variability, and the potential of a genetic risk score to forecast it, ultimately allowing us to predict responses to different anti-obesity interventions.
Celiac artery mesenteric fat measurement with endosonography (CAMEUS) reliably correlates with obesity and related comorbidities
Bazerbachi, Fateh , Baroud, Serge , Levy, Michael J. , Maselli, Daniel B. , Bofill-García, Aliana, Law, Ryan , Chandrasekhara, Vinay , Gleeson, Ferga C. , Rajan, Elizabeth , Iyer, Prasad G. , Watt, Kymberly D. , Law, Ryan J, Chandrasekhara, Vinay , Bazerbachi, F , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Gastroenterology Report | April 26, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1093/gastro/goae039 | PMID 38681751 Get It

Abstract Background Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity. We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscopic ultrasound (EUS), and if these measurements correlate with metabolic disease burden. Methods This was a retrospective analysis of patients who underwent celiac artery mesenteric fat measurement with endosonography (CAMEUS) measurement at a tertiary referral center, and a validation prospective trial of patients with obesity and nonalcoholic steatohepatitis who received paired EUS exams with CAMEUS measurement before and after six months of treatment with an intragastric balloon. Results CAMEUS was measured in 154 patients [56.5% females, mean age 56.5 ± 18.0 years, body mass index (BMI) 29.8 ± 8.0 kg/m2] and was estimated at 14.7 ± 6.5 mm. CAMEUS better correlated with the presence of non-alcoholic fatty liver disease (NAFLD) (R2 = 0.248, P &lt; 0.001) than BMI (R2 = 0.153, P &lt; 0.001), and significantly correlated with metabolic parameters and diseases. After six months of intragastric balloon placement, the prospective cohort experienced 11.7% total body weight loss, 1.3 points improvement in hemoglobin A1c (P = 0.001), and a 29.4% average decrease in CAMEUS (−6.4 ± 5.2 mm, P &lt; 0.001). CAMEUS correlated with improvements in weight (R2 = 0.368), aspartate aminotransferase to platelet ratio index (R2 = 0.138), and NAFLD activity score (R2 = 0.156) (all P &lt; 0.05). Conclusions CAMEUS is a novel measure that is significantly correlated with critical metabolic indices and can be easily captured during routine EUS to risk-stratify susceptible patients. This station could allow for EUS access to sampling and therapeutics of this metabolic region.
Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty
Gala, Khushboo , Brunaldi, Vitor , Ghusn, Wissam , Vargas, Eric J. , Storm, Andrew C. , Acosta, Andrés , Dayyeh, Barham K. Abu

Mayo Clinic

Therapeutic Advances in Gastrointestinal Endoscopy | April 26, 2024 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/26317745241247175 | PMID 38682042 Get It

Background: Endoscopic sleeve gastroplasty (ESG) is a safe and effective obesity treatment. The individualized metabolic score (IMS) is a validated score that uses preoperative variables predicting T2D remission (DR) in bariatric surgery. Objectives: We evaluated the applicability of using the IMS score to predict DR in patients after ESG. Design/Methods: We performed a retrospective review of patients with obesity and T2D who underwent ESG. We calculated DR, IMS score, and severity, and divided patients based on IMS category. Results: The cohort comprised 20 patients: 25% (5) mild, 55% (11) moderate, and 20% (4) severe IMS stages. DR was achieved in 60%, 45.5%, and 0% of patients with mild, moderate, and severe IMS scores ( p = 0.08), respectively. IMS score was significantly associated with DR ( p = 0.03), with the area under the curve of the receiver operating characteristic for predicting DR 0.85. Conclusion: These pilot data demonstrate that the IMS score appears to be useful in predicting DR after ESG.
Endoscopic transoral outlet reduction induces enterohormonal changes in patients with weight regain after Roux-en-Y gastric bypass
Brunaldi, Vitor , Farias, Galileu F. , Santo, Marco Aurélio , Antonângelo, Leila , Waitzberg, D.L., Moura, Eduardo Guimarães Hourneaux de , Brunaldi, Vitor Ottoboni , Faria, Galileu , de Moura, Diogo , de Moura, Eduardo , Dayyeh, Barham K. Abu , Faria, Caroline Silvério

Mayo Clinic

Endoscopy International Open | April 23, 2024 | Volume: 12 | Issue: 05 | Pages: E687-E696

10.1055/a-2312-5742 | PMID 38812699 Get It

Abstract Background and study aims Transoral outlet reduction (TORe) has long been employed in treating weight regain after Roux-en-Y gastric bypass. However, its impact on gut hormones and their relationship with weight loss remains unknown. Patients and methods This was a substudy of a previous randomized clinical trial. Adults with significant weight regain and dilated gastrojejunostomy underwent TORe with argon plasma coagulation (APC) alone or APC plus endoscopic suturing (APC-suture). Serum levels of ghrelin, GLP-1, and PYY were assessed at fasting, 30, 60, 90, and 120 minutes after a standardized liquid meal. Results were compared according to allocation group, clinical success, and history of cholecystectomy. Results Thirty-six patients (19 APC vs. 17 APC-suture) were enrolled. There were no significant baseline differences between groups. In all analyses, the typical postprandial decrease in ghrelin levels was delayed by 30 minutes, but no other changes were noted. GLP-1 levels significantly decreased at 12 months in both allocation groups. Similar findings were noted after dividing groups according to the history of cholecystectomy and clinical success. The APC cohort presented an increase in PYY levels at 90 minutes, while the APC-suture group did not. Naïve patients had significantly lower PYY levels at baseline (P = 0.01) compared with cholecystectomized individuals. This latter group experienced a significant increase in area under the curve (AUC) for PYY levels, while naïve patients did not, leading to a higher AUC at 12 months (P = 0.0001). Conclusions TORe interferes with the dynamics of gut hormones. APC triggers a more pronounced enteroendocrine response than APC-suture, especially in cholecystectomized patients.
Endoscopic Ultrasound-based Shear Wave Elastography for Detection of Advanced Liver Disease
Chin, Jerry Yung‐Lun , Kaur, Jyotroop, Law, Ryan , Garimella, Vishal, Levy, Michael J. , Dierkhising, Ross , Venkatesh, Sudhakar, AbiMansour, Jad P. , Vargas, Eric J. , Dayyeh, Barham K. Abu , Storm, Andrew C. , Allen, Alina M. , Venkatesh, Sudhakar K. , Chandrasekhara, Vinay

Mayo Clinic

Journal of Clinical Gastroenterology | April 22, 2024 | Volume: 59 | Issue: 3 | Pages: 256-261

10.1097/mcg.0000000000002013 | PMID 38648501 Get It

Background and Aims: Endoscopic ultrasound shear wave elastography (EUS-SWE) is a novel modality for liver stiffness measurement. The aims of this study are to evaluate the performance and reliability of EUS-SWE for detecting advanced liver disease in a prospective cohort. Methods: EUS-SWE measurements were prospectively obtained from patients undergoing EUS between August 2020 and March 2023. Liver stiffness measurements were compared between patients with and without advanced liver disease (ALD), defined as stage ≥3, to determine diagnostic accuracy for advanced fibrosis and portal hypertension. Logistic regression was performed to identify variables that impact the reliability of EUS-SWE readings. Select patients underwent paired magnetic resonance elastography (MRE) for liver fibrosis correlation. Results: Patients with ALD demonstrated higher liver stiffness compared to healthy controls (left lobe: 17.6 vs. 12.7 kPa, P <0.001; median right lobe: 24.8 vs. 11.0 kPa, P <0.001). The area under the receiver operator characteristic (AUROC) for the detection of ALD was 0.73 and 0.80 for left and right lobe measurements, respectively. General anesthesia was associated with reliable EUS-SWE liver readings (odds ratio: 2.73, 95% CI: 1.07-7.39, P =0.040). Left lobe measurements correlated significantly with MRE with an increase of 0.11 kPa (95% CI: 0.05-0.17 kPA) for every 1 kPa increase on EUS-SWE. D. Conclusions: SWE is a promising technology that can readily be incorporated into standard EUS examinations for the assessment of ALD.
Gut motility and hormone changes after bariatric procedures
Gala, Khushboo, Gala, Khushboo , Ghusn, Wissam , Dayyeh, Barham K. Abu

Mayo Clinic

Current Opinion in Endocrinology, Diabetes & Obesity | March 27, 2024 | Volume: 31 | Issue: 3 | Pages: 131-137

10.1097/med.0000000000000860 | PMID 38533785 Get It

Purpose of review Metabolic and bariatric surgery (MBS) and endoscopic bariatric therapies (EBT) are being increasingly utilized for the management of obesity. They work through multiple mechanisms, including restriction, malabsorption, and changes in the gastrointestinal hormonal and motility. Recent findings Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) cause decrease in leptin, increase in GLP-1 and PYY, and variable changes in ghrelin (generally thought to decrease). RYGB and LSG lead to rapid gastric emptying, increase in small bowel motility, and possible decrease in colonic motility. Endoscopic sleeve gastroplasty (ESG) causes decrease in leptin and increase in GLP-1, ghrelin, and PYY; and delayed gastric motility. Summary Understanding mechanisms of action for MBS and EBT is critical for optimal care of patients and will help in further refinement of these interventions.